GIFT Study: Genetic Testing Viable For Personalizing Antiplatelet Therapy
This article was originally published in The Gray Sheet
Executive Summary
A recent study supports a role for genetic testing as a means of personalizing antiplatelet therapy following stent placement and builds the case that newer drugs, such as Eli Lilly/Daiichi Sankyo's Effient (prasugrel), are more appropriate options for those who have poor response to standard Plavix (clopidogrel) treatment.
You may also be interested in...
Tgen, Dell Partner To Combine Genomics With Cloud Computing For Personalized Medicine
Two trials testing Tgen’s approach to using genomics algorithms to help select cancer treatments are ongoing. The further ambition is to unite outcomes data in electronic health records and genomics data to get an even more personalized view of what’s going on with a patient.
TCT Late-Breaker: Point-Of-Care Genetic Test Guides Antiplatelet Therapy
Data presented at the Transcatheter Cardiovascular Therapeutics meeting may support rapid, point-of-care genetic testing in tailoring antiplatelet therapy, but clinicians are still not convinced.
TCT Late-Breaker: Point-Of-Care Genetic Test Guides Antiplatelet Therapy
Data presented at TCT may support rapid, point-of-care genetic testing in tailoring antiplatelet therapy, but clinicians are still not convinced.